Archives of dermatological research · 2025
Hair regeneration in androgenetic alopecia using secretome of adipose-derived stem cells (ADSC) and minoxidil: a comparative study of three groups.
Клиническое исследованиеСравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Legiawati Lili, Sitohang Irma Bernadette S, Yusharyahya Shannaz Nadia, Sirait Sondang P, Novianto Endi, Liem Isabella Kurnia, Kurniawati Trie, Putri Ines Soepinarko, Rahmadika Faizal Dzaky, Hakiki Nadhira Permata, Lauren Brigitta Cindy
Аннотация
Androgenetic alopecia is one of the most common cause of hair loss disorder. This hereditary and androgen-dependent disorder tends to progress into partial or even complete baldness Several therapeutic options are now available for AGA, including conventional medications such as finasteride, dutasteride, and minoxidil. However, side effects of these medications are also commonly reported. The use of adipose derived stem cells and their secreted bioactive molecules, "secretome" has gained attention which could produce many effects for hair growth promotion and has been proven in clinical trials. This study aims to compare the effectiveness and safety of with minoxidil in androgenetic alopecia cases. 60 subjects were divided into three treatment groups (minoxidil only, secretome only, and combination of both) and were given intervention on week 0, 4, and 8. All subjects were evaluated by physical examination, photography, trichoscopy, and trichoscan until week 12. All groups showed a statistically significant improvement (p < 0.05) on hair growth parameters with the best improvement observed on week 12. The combination group had the best improvement substantially on hair growth parameters. Side effects are minimum and reported by the subjects in minoxidil group. Clinicaltrials.gov, NCT06066827. Registered 05 October 2023, Retrospectively. https://register.clinicaltrials.gov/prs/app/template/Home.vm?uid=U0004ES6_ts=7_sid=S000DOK9_cx=-igh2d .